HBNC vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HBNC presents a stark contradiction between valuation and fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock appears undervalued with a Forward P/E of 8.07 and a PEG of 0.80, the negative ROE (-20.73%) and ROA (-2.11%) indicate significant operational inefficiency or temporary distress. Despite astronomical revenue growth (218.7%), earnings are declining YoY (-18.5%), suggesting that top-line expansion is not translating to profitability. The technical trend is currently bearish (0/100), offsetting the positive analyst target of $20.80.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HBNC vs JPM: Head-to-Head Comparison
This page compares Horizon Bancorp, Inc. (HBNC) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.